Cargando…

PAM50 intrinsic subtypes, risk of recurrence score and breast cancer survival in HIV-positive and HIV-negative patients—a South African cohort study

PURPOSE: Treatment decision making for patients with breast cancer increasingly depends on analysis of markers or systems for estimating risk of breast cancer recurrence. Breast cancer intrinsic subtypes and risk of recurrence (ROR) scores have been found to be valuable in predicting survival and de...

Descripción completa

Detalles Bibliográficos
Autores principales: Phakathi, Boitumelo, Dix-Peek, Therese, Van Den Berg, Eunice, Dickens, Caroline, Nietz, Sarah, Cubasch, Herbert, Joffe, Maureen, Neugut, Alfred I., Jacobson, Judith S., Ruff, Paul, Duarte, Raquel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300149/
https://www.ncbi.nlm.nih.gov/pubmed/37266756
http://dx.doi.org/10.1007/s10549-023-06969-1
_version_ 1785064525426327552
author Phakathi, Boitumelo
Dix-Peek, Therese
Van Den Berg, Eunice
Dickens, Caroline
Nietz, Sarah
Cubasch, Herbert
Joffe, Maureen
Neugut, Alfred I.
Jacobson, Judith S.
Ruff, Paul
Duarte, Raquel
author_facet Phakathi, Boitumelo
Dix-Peek, Therese
Van Den Berg, Eunice
Dickens, Caroline
Nietz, Sarah
Cubasch, Herbert
Joffe, Maureen
Neugut, Alfred I.
Jacobson, Judith S.
Ruff, Paul
Duarte, Raquel
author_sort Phakathi, Boitumelo
collection PubMed
description PURPOSE: Treatment decision making for patients with breast cancer increasingly depends on analysis of markers or systems for estimating risk of breast cancer recurrence. Breast cancer intrinsic subtypes and risk of recurrence (ROR) scores have been found to be valuable in predicting survival and determining optimal treatment for individual patients. We studied the association of breast cancer survival with the PAM50 gene expression assay in HIV-positive and HIV-negative patients. METHOD: RNA was extracted from formalin-fixed paraffin-embedded specimens of histologically confirmed invasive carcinoma and was purified using the AllPrep® DNA/RNA FFPE kit, Qiagen (Hilden, Germany). The NanoString RUO PAM50 algorithm was used to determine the molecular subtype and the risk of recurrence score of each sample. The overall and disease-free survival were determined with comparison made among HIV-positive and -negative patients. We then generated Kaplan–Meier survival curves, calculated p-values and estimated hazard ratios and their 95% confidence intervals using Cox regression models. RESULTS: Of the 384 RNA samples analysed, 98.4% met the required RNA quality standard and the specified QC threshold for the test. Luminal B was the most common PAM50 intrinsic subtype and 82.1% of patients were at high risk for disease recurrence based on ROR score. HIV infection, PAM50-based HER2-enriched and basal-like intrinsic subtypes, and high ROR were associated with poor overall and disease-free survival. HIV-positive patients with luminal A & B subtypes had significantly worse survival outcomes than HIV-negative luminal patents. CONCLUSION: Aggressive tumour biology was common in our cohort. HIV infection, PAM50 HER2-enriched,basal-like intrinsic subtypes and high ROR score were associated with poor overall and disease-free survival. HIV infection impacted survival in patients with luminal subtypes only.
format Online
Article
Text
id pubmed-10300149
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-103001492023-06-29 PAM50 intrinsic subtypes, risk of recurrence score and breast cancer survival in HIV-positive and HIV-negative patients—a South African cohort study Phakathi, Boitumelo Dix-Peek, Therese Van Den Berg, Eunice Dickens, Caroline Nietz, Sarah Cubasch, Herbert Joffe, Maureen Neugut, Alfred I. Jacobson, Judith S. Ruff, Paul Duarte, Raquel Breast Cancer Res Treat Original Laboratory Investigation PURPOSE: Treatment decision making for patients with breast cancer increasingly depends on analysis of markers or systems for estimating risk of breast cancer recurrence. Breast cancer intrinsic subtypes and risk of recurrence (ROR) scores have been found to be valuable in predicting survival and determining optimal treatment for individual patients. We studied the association of breast cancer survival with the PAM50 gene expression assay in HIV-positive and HIV-negative patients. METHOD: RNA was extracted from formalin-fixed paraffin-embedded specimens of histologically confirmed invasive carcinoma and was purified using the AllPrep® DNA/RNA FFPE kit, Qiagen (Hilden, Germany). The NanoString RUO PAM50 algorithm was used to determine the molecular subtype and the risk of recurrence score of each sample. The overall and disease-free survival were determined with comparison made among HIV-positive and -negative patients. We then generated Kaplan–Meier survival curves, calculated p-values and estimated hazard ratios and their 95% confidence intervals using Cox regression models. RESULTS: Of the 384 RNA samples analysed, 98.4% met the required RNA quality standard and the specified QC threshold for the test. Luminal B was the most common PAM50 intrinsic subtype and 82.1% of patients were at high risk for disease recurrence based on ROR score. HIV infection, PAM50-based HER2-enriched and basal-like intrinsic subtypes, and high ROR were associated with poor overall and disease-free survival. HIV-positive patients with luminal A & B subtypes had significantly worse survival outcomes than HIV-negative luminal patents. CONCLUSION: Aggressive tumour biology was common in our cohort. HIV infection, PAM50 HER2-enriched,basal-like intrinsic subtypes and high ROR score were associated with poor overall and disease-free survival. HIV infection impacted survival in patients with luminal subtypes only. Springer US 2023-06-02 2023 /pmc/articles/PMC10300149/ /pubmed/37266756 http://dx.doi.org/10.1007/s10549-023-06969-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Laboratory Investigation
Phakathi, Boitumelo
Dix-Peek, Therese
Van Den Berg, Eunice
Dickens, Caroline
Nietz, Sarah
Cubasch, Herbert
Joffe, Maureen
Neugut, Alfred I.
Jacobson, Judith S.
Ruff, Paul
Duarte, Raquel
PAM50 intrinsic subtypes, risk of recurrence score and breast cancer survival in HIV-positive and HIV-negative patients—a South African cohort study
title PAM50 intrinsic subtypes, risk of recurrence score and breast cancer survival in HIV-positive and HIV-negative patients—a South African cohort study
title_full PAM50 intrinsic subtypes, risk of recurrence score and breast cancer survival in HIV-positive and HIV-negative patients—a South African cohort study
title_fullStr PAM50 intrinsic subtypes, risk of recurrence score and breast cancer survival in HIV-positive and HIV-negative patients—a South African cohort study
title_full_unstemmed PAM50 intrinsic subtypes, risk of recurrence score and breast cancer survival in HIV-positive and HIV-negative patients—a South African cohort study
title_short PAM50 intrinsic subtypes, risk of recurrence score and breast cancer survival in HIV-positive and HIV-negative patients—a South African cohort study
title_sort pam50 intrinsic subtypes, risk of recurrence score and breast cancer survival in hiv-positive and hiv-negative patients—a south african cohort study
topic Original Laboratory Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300149/
https://www.ncbi.nlm.nih.gov/pubmed/37266756
http://dx.doi.org/10.1007/s10549-023-06969-1
work_keys_str_mv AT phakathiboitumelo pam50intrinsicsubtypesriskofrecurrencescoreandbreastcancersurvivalinhivpositiveandhivnegativepatientsasouthafricancohortstudy
AT dixpeektherese pam50intrinsicsubtypesriskofrecurrencescoreandbreastcancersurvivalinhivpositiveandhivnegativepatientsasouthafricancohortstudy
AT vandenbergeunice pam50intrinsicsubtypesriskofrecurrencescoreandbreastcancersurvivalinhivpositiveandhivnegativepatientsasouthafricancohortstudy
AT dickenscaroline pam50intrinsicsubtypesriskofrecurrencescoreandbreastcancersurvivalinhivpositiveandhivnegativepatientsasouthafricancohortstudy
AT nietzsarah pam50intrinsicsubtypesriskofrecurrencescoreandbreastcancersurvivalinhivpositiveandhivnegativepatientsasouthafricancohortstudy
AT cubaschherbert pam50intrinsicsubtypesriskofrecurrencescoreandbreastcancersurvivalinhivpositiveandhivnegativepatientsasouthafricancohortstudy
AT joffemaureen pam50intrinsicsubtypesriskofrecurrencescoreandbreastcancersurvivalinhivpositiveandhivnegativepatientsasouthafricancohortstudy
AT neugutalfredi pam50intrinsicsubtypesriskofrecurrencescoreandbreastcancersurvivalinhivpositiveandhivnegativepatientsasouthafricancohortstudy
AT jacobsonjudiths pam50intrinsicsubtypesriskofrecurrencescoreandbreastcancersurvivalinhivpositiveandhivnegativepatientsasouthafricancohortstudy
AT ruffpaul pam50intrinsicsubtypesriskofrecurrencescoreandbreastcancersurvivalinhivpositiveandhivnegativepatientsasouthafricancohortstudy
AT duarteraquel pam50intrinsicsubtypesriskofrecurrencescoreandbreastcancersurvivalinhivpositiveandhivnegativepatientsasouthafricancohortstudy